Virus-like particle vaccines against BK and JC polyomaviruses

摘要

1. Indication 1: prevention of polyomavirus nephropathy in transplant patients. Predicted US market $600 million/year 2. Indication 2: prevention of bladder disease after bone marrow transplant. Predicted US market $400 million/year plus an uncertain fraction of 250,000 patients diagnosed with conditions that may require transplant 3. Indication 3: prevention of PML side effects in individuals taking top-selling immunosuppressive therapies. $Billions.